fung_derf
9 months ago
Well THIS is certainly interesting.....you want to sue a poster for giving you misinformation in order to promote a stock price?? And shockingly, you lost money in ANOTHER penny stock??!!
OK , I am posting to the lawyers who always looking to sue the companies..
I want to sue this loser CEO of TBPMF , and his friend ..I don't remember this friend name now , but I invested at the time because of this friend pumping,
I do remember his face from many pumping videos he made before he sold his shares , and I will look until I do find his name..
They both pumped this stock , and then I believe they sold..
I think I lost couple hundreds thousand of doll , and I want to go after them.. I believe they both dishonest , and I am done with this type of people..
If any lawyer representative is reading here , please contact me..
I am done with crooks..I want to go after them both now !!!!
All IMO...
misiu143
2 years ago
OK , I am posting to the lawyers who always looking to sue the companies..
I want to sue this loser CEO of TBPMF , and his friend ..I don't remember this friend name now , but I invested at the time because of this friend pumping,
I do remember his face from many pumping videos he made before he sold his shares , and I will look until I do find his name..
They both pumped this stock , and then I believe they sold..
I think I lost couple hundreds thousand of doll , and I want to go after them.. I believe they both dishonest , and I am done with this type of people..
If any lawyer representative is reading here , please contact me..
I am done with crooks..I want to go after them both now !!!!
All IMO...
Buellersback
2 years ago
REDUVO™ Marketing Approval on the Right Path
12/22/2022
Second Clarifax received from Health Canada.
MONTREAL, Dec. 22, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with another regulatory update on the REDUVO™ New Drug Submission (NDS). The last update was provided on November 18, 2022.
Tetra Bio-Pharma Logo (CNW Group/Tetra Bio-Pharma Inc.)
On December 21, 2022, the Company received a second Clarification Request (Clarifax) from Health Canada regarding the product's Risk Management Plan, which is not atypical for a controlled substance drug. The Company will be submitting the response to Health Canada within the allowed timeframe. The Company cannot comment on Health Canada's response timelines. Questions/feedback from Health Canada are received as the review of the dossier progresses through different review streams.
About REDUVO™
REDUVO™ is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV). It is also used to treat weight loss and severe nausea in people living with HIV infection. The active pharmaceutical ingredient in REDUVO™ is dronabinol, also known as THC, a synthetic form of the active natural substance in cannabis. REDUVO™ 5-year cumulative gross sales expected to reach $121M.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Their evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what they do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.
Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/reduvo-marketing-approval-on-the-right-path-301709009.html
SOURCE Tetra Bio-Pharma Inc.
Emergcy
2 years ago
Here is my letter, which didn't get any reply:
Dear Natalie,
I hope you are in a much better condition than Tetra. I wonder what you think you can tell me:
Initially, your CEO was expecting the Reduvo approval for latest end of 2021. I checked in the meantime the performance of Health Canada and found that in the worst case, the approval process for a drug took 24 months. We will reach the worst case, 24 months, in December 2022. Does your company know that we will even be the new record and take longer than 24 months?
The intermediate results for Reborn - FDA trial- were planned for June 22. You modified the trial twice to be faster than initially seen. We are now 16 months into the trials without any report for results. The performance of Reborn can be seen daily, but no indications are given about enrollment (done or not?) and performance (within expectations or not).
We are approaching the last resistance before we fall over the cliff down to 0.006. Does the CEO want us to fall over the cliff? I trust, Reborn is working, but maybe you can't manage the enrollment. Perhaps something went very wrong?
Maybe the CEO feel burnt after all his promises last year in June failed so dramatically. Even if he doesn't want anymore give predictions some info could keep us alive such following messages:
We still wait for the approval. So far no negative indications that it will not take place.
The Reborn trial is smoothly running; enrollment is very slow, but we have managed so far xy %. After complete enrollment, it will take us another xy months for results.
I think your CEO should consider that people like me and many others invested in Tetra based on excellent preliminary results. We need to come back to a climate of hope and trust.
Could you please let your CEO know?
kindest regards
Emergcy
2 years ago
Thank you for sharing this video.
We all hear and know about Opioide crisis. We have heard extremely promising first results of the Tetra product. It will in many years find its way to the market. Not much doubt.
I am with Leronlimab for more than 5 years. Every expert knows how phantastic this drug works for Covid, Cancer, HIV, TNBC, NASH and many other diseases. It was successful in Phase3 and 2 trials. And? No way to find its way to the market. Big Pharma will not allow to get its business destroyed and FDA collaborates perfectly.
Let's look at Tetra's Reborn trial. It runs for more than 1 year and Tetra has even not reported interim results. There is no way to bypass BP. FDA will find ways to delay for many years, no matter how great Tetra's products are working.
Whatever Gay told us in June 21 was wrong. Yes, the Tetra product is working and is needed desperately but BP will not allow to get it to market. Maybe the new JV can help but still it will take many years.
I invested 2021 because Reborn trial and coming PIN. I was wrong like with Leronlimab. In both my investments were years too early. Gay does what Nader did - telling not the whole true story about great medicine.
Buellersback
2 years ago
Interesting article explaining PPS woes for many biotech companies like TBPMF:
Big Pharma Won't Bail Out Battered Biotech -- Heard on the Street -- WSJ
7:00 am ET June 30, 2022 (Dow Jones) Print
By David Wainer
The stock market might be in the doldrums, but the biotechnology index has fallen off a cliff. One measure says it all: Dozens of publicly traded biotechs have dropped so much that they are now valued below the amount of cash they have in the bank.
Some healthcare investors have been pointing to that trend as a sign things have started to bottom. The argument goes that biotech has become so cheap that big pharma -- staring down a patent cliff and armed with hundreds of billions of dollars of dry powder for acquisitions -- will come to the rescue. Indeed, a popular biotech exchange-traded fund, the SPDR S&P Biotech ETF, has rebounded by around 20% from its recent lows.
That analysis paints with too broad a brush. Many of the companies now trading below cash are likely to go out of business in a macroeconomic environment in which their key input cost -- money -- is rising. To an even greater degree than high-growth tech companies such as Shopify or Roblox, biotech struggles in a rising interest-rate environment because many companies don't have any real revenue streams and don't expect to have a product in the market for years. Sadly for both investors and patients, clinical trials move slowly.
That problem has been exacerbated by a biotech bubble in recent years as too many early-stage companies went public. In 2021, the peak bubble year, 111 biotechs had initial public offerings in the U.S., topping the previous peak of 91 in 2020. Some of those companies are still conducting preclinical trials, meaning they haven't even begun testing their therapies on humans.
Sio Gene Therapies, with its shares down 87% in the past year, is an example of a company trading at a negative enterprise value. Sio Gene's market capitalization is $27 million, even though it had $65 million in the bank as of the end of the first quarter.
But Sio Gene is anything but a bargain. The company has terminated its gene therapy licensing agreements with the University of Massachusetts, is quickly running out of cash, and has fired much of its staff. Because a company like Sio Gene is effectively locked out of the capital markets these days, it needs to find a buyer to bail it out. The company hired SVB Securities in late April to help it explore a sale. Whether it can survive in some form remains to be seen.
Sio Gene isn't alone. Fierce Biotech, a news outlet focused on the industry, started a layoff tracker this year, and it looks scary. In the first week of June, for instance, oncology biotech Atreca announced plans to cull a quarter of its workforce and stem-cell developer Athersys said it is cutting 70% of its staff. And the list goes on.
So when will the bleeding stop? For Les Funtleyder, a healthcare investor at E Squared Capital Management, the sector as a whole can't really begin to rebound until it is clear that the Federal Reserve is finished raising rates. As of now, traders are pricing in rate cuts later next year, so a recovery could start early next year, he says. Pharma companies, Mr. Funtleyder says, aren't particularly focused on valuations. What they are focused on is the science and whether the business is a strategic fit.
Of course the market rout leaves some solid biotech businesses trading at bargain prices. That means the deal pace will probably pick up this year, especially in the crowded oncology space. Ipsen has agreed to acquire Epizyme for $247 million, and Bristol-Myers Squibb said it would buy Turning Point Therapeutics for $4.1 billion. Both are cancer plays. While the Turning Point deal reflected a premium, the purchase price was still below last year's high. Much of the most recent strength in the biotechnology sector has been related to speculation that Merck & Co. might buy Seagen, a company that could fetch about $40 billion.
But pharma companies are looking for needles in the haystack, not the haystack itself. That means more pain could still be coming for biotech investors. Big pharma won't be there to help.
CFRA Research Disclosure
3rd Party Research Disclosure
Level up your trading with our powerful tools and real-time insights all in one place.
Ask ADVFN Intelligence (AI)
Netcool
6 months ago
Renee
1 year ago
AJ Freely
1 year ago
d0lphint0m
2 years ago
Hot Features
Premium
